Multiple Myeloma in Relapse Clinical Trial
Official title:
Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | November 1, 2026 |
Est. primary completion date | November 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (2020.v2); 2. Relapsed or refractory B cell hematological malignancies (meeting one of the following conditions): 1. CR not achieved after standardized chemotherapy; 2. CR achieved following the first induction, but CR duration is less than 12 months; 3. Ineffectively after first or multiple remedial treatments; 4. 2 or more relapses; 5. Relapse after hematopoietic stem cell transplantation; 6. Extramedullary leisions which were ineffective to radiotherapy or chemotherapy; 3. Total bilirubin = 51 umol/L, ALT and AST = 3 times of upper limit ofnormal, creatinine = 176.8 umol/L; 4. Echocardiogram shows left ventricular ejection fraction (LVEF) =50%; 5. No active infection in the lungs, blood oxygen saturation in indoorair is = 92%; 6. Estimated survival time = 12 weeks; 7. ECOG performance status 0 to 2; 8. Women of childbearing age had negative pregnancy test during screening period and before administration, and agreed to take effective contraceptive measures at least one year after infusion. 9. Patients volunteer to participate in the study and sign the informed consent. Exclusion Criteria: Subjects with any of the following exclusion criteria were not eligible for this trial: 1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases; 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; 3. Pregnant (or lactating) women; 4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); 5. Active infection of hepatitis B virus or hepatitis C virus; 6. Concurrent therapy with systemic steroids within 2 weeks prior toscreening, except for the patients recently or currently receiving in haledsteroids; 7. Previously treated with any CAR-T cell product or other genetically-modified T cell therapies; 8. Creatinine >2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin >2.0 mg/dl; 9. Other uncontrolled diseases that were not suitable for this trial; 10. Patients with HIV infection; 11. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study. |
Country | Name | City | State |
---|---|---|---|
China | The First Hospital of Zhejiang Medical Colleage Zhejiang University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang University | Yake Biotechnology Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity (DLT) | Adverse events assessed according to NCI-CTCAE v5.0 criteria | Baseline up to 28 days after CAR T-cells infusion | |
Primary | Incidence of treatment-emergent adverse events (TEAEs) | Incidence of treatment-emergent adverse events [Safety and Tolerability] | Up to 2 years after CAR T-cells infusion | |
Secondary | B-cell acute lymphocytic leukemia(B-ALL), Overall response rate (ORR) | Assessment of ORR (ORR = CR + CRi) at Month 6, 12, 18 and 24 | At Month 1, 3, 6, 12, 18 and 24 | |
Secondary | B-ALL, Overall survival (OS) | From the first infusion of CAR-T cells to death or the last visit | Up to 2 years after CAR-T cells infusion | |
Secondary | B-ALL, Event-free survival (EFS) | From the first infusion of CAR-T cells to the occurrence of any event, including death, relapse orgene relapse, disease progression (any one occurs first), and the last visit | Up to 2 years after CAR-T cells infusion | |
Secondary | B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR) | Assessment of ORR (ORR = CR + PR) per Lugano 2014 criteria | At Week 4, 12, and Month 6, 12, 18, 24 | |
Secondary | B-NHL, disease control rate (DCR) | Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria | At Week 12 and Month 6, 12, 18, 24 | |
Secondary | Multiple myeloma (MM), Overall response rate (ORR) | Assessment of ORR at Day 28 | At Day 28 | |
Secondary | MM, Overall survival (OS) | Assessment of OS at Month 6, 12, 24 | At Month 6, 12, 24 | |
Secondary | Quality of life | Assessment using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scale [For item1-28: max score: 112, min score: 28, higher scores mean a better outcome; for item 28-29: max score: 14, min score: 2, higher scores mean a worse outcome] to measure Quality of life at Baseline, Month 1, 3, 6, 9 and 12 | At Baseline, Month 1, 3, 6, 9 and 12 | |
Secondary | Activities of Daily Living (ADL) score | Assessment using Activities of Daily Living (ADL) scale (Barthel Index) [max score: 100, min score: 0, higher scores mean a better outcome] at Baseline, Month 1, 3, 6, 9 and 12 | At Baseline, Month 1, 3, 6, 9 and 12 | |
Secondary | Instrumental Activities of Daily Living (IADL) score | Assessment of Instrumental Activities of Daily Living (IADL) scale [max score: 56, min score: 14, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12 | At Baseline, Month 1, 3, 6, 9 and 12 | |
Secondary | Hospital Anxiety and Depression Scale (HADS) score | Assessment using Hospital Anxiety and Depression Scale (HADS) [max score: 42, min score: 0, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12 | At Baseline, Month 1, 3, 6, 9 and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01435720 -
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04094961 -
Ixazomib + Pomalidomide + Dexamethasone In MM
|
Phase 1/Phase 2 | |
Recruiting |
NCT06068400 -
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
|
N/A | |
Recruiting |
NCT03601624 -
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
|
Phase 2 | |
Recruiting |
NCT05020444 -
TriPRIL CAR T Cells in Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT03706547 -
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
|
Phase 1 | |
Active, not recruiting |
NCT02970747 -
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
|
||
Not yet recruiting |
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 | |
Completed |
NCT01965353 -
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT05581875 -
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
|
Phase 1/Phase 2 | |
Terminated |
NCT03687125 -
Tinostamustine Conditioning and Autologous Stem Cell
|
Phase 1/Phase 2 | |
Recruiting |
NCT06282978 -
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
|
Phase 2 | |
Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT03030261 -
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04925193 -
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
Completed |
NCT03136653 -
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04162353 -
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
|
Phase 1 |